PowerPoint Slides for: Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study
Alshahawey M.
Shahin S.M.
Elsaid T.W.
Sabri N.A.
10.6084/m9.figshare.5017127.v1
https://karger.figshare.com/articles/dataset/PowerPoint_Slides_for_Effect_of_Febuxostat_on_the_Endothelial_Dysfunction_in_Hemodialysis_Patients_A_Randomized_Placebo-Controlled_Double-Blinded_Study/5017127
<p><b><i>Background:</i></b> Endothelial dysfunction is an important
risk factor for cardiovascular diseases to occur in end-stage renal
disease patients. Febuxostat, being a novel xanthine oxidase inhibitor,
is apparently having a beneficial role in improving the endothelial
dysfunction; however, data among hemodialysis patients are still
limited. <b><i>Methods:</i></b> A prospective, placebo-controlled,
block-randomized, double-blinded study was carried out to evaluate the
effect of oral febuxostat on the endothelial dysfunction in hemodialysis
patients. Fifty-seven eligible hemodialysis patients were randomly
assigned to either the drug group (40 mg thrice weekly) or the placebo
group. Serum Asymmetric dimethylarginine (ADMA), Serum uric acid (UA),
and serum high sensitivity C-reactive protein (hsCRP) were measured at
baseline and at the end of a 2-month study. Serum alanine
aminotransferase (ALT), serum aspartate aminotransferase (AST), and the
occurrence of pancytopenia were tested as safety parameters at baseline
and at the end of study. <b><i>Results:</i></b> Serum UA significantly
decreased from 7.5 ± 0.8 to 5.1 ± 1.2 mg/dL in the febuxostat group,
while it did not change significantly in the placebo group. Treatment
with febuxostat resulted in a significant decrease in the serum ADMA
level from 1.027 ± 0.116 to 0.944 ± 0.104 µmol/L and the serum hsCRP
level from 12.5 ± 1.65 to 12.1 ± 1.70 mg/L. Testing of serum ALT, serum
AST, and pancytopenia revealed no significant difference in both groups.
<b><i>Conclusion:</i></b> Febuxostat appears to improve hyperuricemia
and endothelial dysfunction and ameliorate inflammation in hemodialysis
patients with no safety concerns.</p>
2017-05-18 13:48:13
Hemodialysis
Febuxostat
Endothelial dysfunction
Asymmetric dimethylarginine
Hyperuricemia
Inflammation